Drug Profile
Research programme: factor Xa inhibitor - Sanofi-Aventis
Alternative Names: SAR 377142Latest Information Update: 18 Mar 2009
Price :
$50
*
At a glance
- Originator sanofi-aventis
- Class
- Mechanism of Action Factor Xa inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Thromboembolism
Most Recent Events
- 18 Mar 2009 No development reported - Preclinical for Thromboembolism in Europe (PO)
- 25 May 2006 Preclinical trials in Thromboembolism in Europe (PO)